ALPMF (Astellas Pharma) Gross Profit : $9,759 Mil (TTM As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Gross Profit?

Astellas Pharma's gross profit for the three months ended in Sep. 2024 was $2,657 Mil. Astellas Pharma's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $9,759 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Astellas Pharma's gross profit for the three months ended in Sep. 2024 was $2,657 Mil. Astellas Pharma's Revenue for the three months ended in Sep. 2024 was $3,235 Mil. Therefore, Astellas Pharma's Gross Margin % for the quarter that ended in Sep. 2024 was 82.12%.

Astellas Pharma had a gross margin of 82.12% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Astellas Pharma was 81.78%. The lowest was 73.29%. And the median was 78.19%.

Astellas Pharma Gross Profit Historical Data

The historical data trend for Astellas Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Gross Profit Chart

Astellas Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Gross Profit

Get a 7-Day Free Trial

9,511.75

9,231.59

8,797.24

9,204.15

8,751.83

Astellas Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross Profit	Get a 7-Day Free Trial															2,149.12	2,403.33	2,278.58	2,419.79	2,656.85

Competitive Comparison of Astellas Pharma's Gross Profit

For the Drug Manufacturers - General subindustry, Astellas Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Gross Profit falls into.

Astellas Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Astellas Pharma's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )	=	Revenue	-	Cost of Goods Sold
	=	10704.091	-	1952.26
	=	8,752

Astellas Pharma's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )	=	Revenue	-	Cost of Goods Sold
	=	3235.285	-	578.437
	=	2,657

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,759 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Astellas Pharma's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )	=	Gross Profit (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	2,657	/	3235.285
	=	82.12 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Astellas Pharma (OTCPK:ALPMF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Astellas Pharma had a gross margin of 82.12% for the quarter that ended in Sep. 2024 => Durable competitive advantage

Astellas Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.